Search Results
Search for other papers by Yi Wang in
Google Scholar
PubMed
Search for other papers by Yingying Xu in
Google Scholar
PubMed
Search for other papers by Rongrong Xie in
Google Scholar
PubMed
Search for other papers by Bing Yan Cao in
Google Scholar
PubMed
Search for other papers by Yuan Ding in
Google Scholar
PubMed
Search for other papers by Jiayun Guo in
Google Scholar
PubMed
Search for other papers by Xiaoqiao Li in
Google Scholar
PubMed
Search for other papers by Xiaolin Ni in
Google Scholar
PubMed
Search for other papers by Zheng Yuan in
Google Scholar
PubMed
Search for other papers by Linqi Chen in
Google Scholar
PubMed
Search for other papers by Liyang Liang in
Google Scholar
PubMed
Search for other papers by Chunxiu Gong in
Google Scholar
PubMed
Objective: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, and autonomic dysregulation (ROHHAD) is rare, and manifestations of autonomic dysregulation are diverse and may be overlooked. We aimed to evaluate the incidence of these manifestations.
Methods: Patients with ROHHAD syndrome reported before and after 2019 were divided into Groups 1 and 2. Patients who were diagnosed at three regional hospitals in China were included in Group 3. We collected the age of each specific term of the ROHHAD (neurogenic tumor, NET) acronym and the detailed manifestations of each term, and compared them among the three groups.
Results: A total of 16 patients were diagnosed within the 2-year period. Two had neurogenic tumors and cognitive and behavioral abnormalities before developing rapid obesity. At least 93.8% of the patients had ≥ 4 symptoms of autonomic dysregulation. When comparing autonomic dysregulation among Groups 1–3, the rates of cardiovascular manifestations were NA vs. 12.8% vs. 81.2%; gastrointestinal disturbances were 11.4% vs. 8.5% vs. 62.5%; strabismus was 25.7% vs. 12.8% vs. 62.5%; sleep disturbance was NA vs. 6.4% vs. 50.0%; and abnormal pain threshold was NA vs. 10.6% vs. 25.0% (all p<0.05). The rates of cognitive and behavioral abnormalities were NA vs 29.8% and 87.5% (p<0.01).
Conclusions: Rapid-onset obesity is not always the first sign of ROHHAD syndrome. Higher rates of autonomic dysregulation and cognitive and behavioral abnormalities with multiple manifestations of autonomic dysregulation coexisted in our cohort, indicating that evaluations of autonomic function and the limbic system should be strengthened when assessing this condition.
Search for other papers by Xue-Lian Zhang in
Google Scholar
PubMed
Search for other papers by Xinyi Zhao in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Yong Wu in
Google Scholar
PubMed
Search for other papers by Wen-qing Huang in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Jun-jiang Chen in
Google Scholar
PubMed
Search for other papers by Peijie Hu in
Google Scholar
PubMed
Search for other papers by Wei Liu in
Google Scholar
PubMed
Search for other papers by Yi-Wen Chen in
Google Scholar
PubMed
Search for other papers by Jin Hao in
Google Scholar
PubMed
Search for other papers by Rong-Rong Xie in
Google Scholar
PubMed
Search for other papers by Hsiao Chang Chan in
Google Scholar
PubMed
Search for other papers by Ye Chun Ruan in
Google Scholar
PubMed
Search for other papers by Hui Chen in
Google Scholar
PubMed
Search for other papers by Jinghui Guo in
Google Scholar
PubMed
Objective
The beneficial effect of angiotensin(1–7) (Ang(1–7)), via the activation of its receptor, MAS-1, has been noted in diabetes treatment; however, how Ang(1–7) or MAS-1 affects insulin secretion remains elusive and whether the endogenous level of Ang(1–7) or MAS-1 is altered in diabetic individuals remains unexplored. We recently identified an important role of cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated Cl− channel, in the regulation of insulin secretion. Here, we tested the possible involvement of CFTR in mediating Ang(1–7)’s effect on insulin secretion and measured the level of Ang(1–7), MAS-1 as well as CFTR in the blood of individuals with or without type 2 diabetes.
Methods
Ang(1–7)/MAS-1/CFTR pathway was determined by specific inhibitors, gene manipulation, Western blotting as well as insulin ELISA in a pancreatic β-cell line, RINm5F. Human blood samples were collected from 333 individuals with (n = 197) and without (n = 136) type 2 diabetes. Ang(1–7), MAS-1 and CFTR levels in the human blood were determined by ELISA.
Results
In RINm5F cells, Ang(1–7) induced intracellular cAMP increase, cAMP-response element binding protein (CREB) activation, enhanced CFTR expression and potentiated glucose-stimulated insulin secretion, which were abolished by a selective CFTR inhibitor, RNAi-knockdown of CFTR, or inhibition of MAS-1. In human subjects, the blood levels of MAS-1 and CFTR, but not Ang(1–7), were significantly higher in individuals with type 2 diabetes as compared to those in non-diabetic healthy subjects. In addition, blood levels of MAS-1 and CFTR were in significant positive correlation in type-2 diabetic but not non-diabetic subjects.
Conclusion
These results suggested that MAS-1 and CFTR as key players in mediating Ang(1–7)-promoted insulin secretion in pancreatic β-cells; MAS-1 and CFTR are positively correlated and both upregulated in type 2 diabetes.
Search for other papers by Qiuli Liu in
Google Scholar
PubMed
Search for other papers by Lin-ang Wang in
Google Scholar
PubMed
Search for other papers by Jian Su in
Google Scholar
PubMed
Search for other papers by Dali Tong in
Google Scholar
PubMed
Search for other papers by Weihua Lan in
Google Scholar
PubMed
Search for other papers by Luofu Wang in
Google Scholar
PubMed
Search for other papers by Gaolei Liu in
Google Scholar
PubMed
Search for other papers by Jun Zhang in
Google Scholar
PubMed
AmCare Genomics Lab, Guangzhou, People’s Republic of China
Search for other papers by Victor Wei Zhang in
Google Scholar
PubMed
Search for other papers by Dianzheng Zhang in
Google Scholar
PubMed
Search for other papers by Rongrong Chen in
Google Scholar
PubMed
Search for other papers by Qingyi Zhu in
Google Scholar
PubMed
Search for other papers by Jun Jiang in
Google Scholar
PubMed
Congenital adrenal hyperplasia (CAH) is one of the most prevalent, and potentially severe, genetic inborn errors of steroid synthesis directly affecting metabolism. Most patients are diagnosed and treated at an early age. There have been very limited reports of adults with CAH-associated adrenal myelolipomas. We aimed to analyze two families with CAH-associated giant adrenal myelolipomas caused by defects in CYP21A2 and CYP17A1 genes. A total of 14 individuals from two unrelated families were identified with either CYP21A2 or CYP17A1 mutations. Of note, five patients were found with adrenal myelolipomas. Total DNA isolated from the peripheral blood of the two probands was screened for potential mutations in the following susceptibility genes of CAH: CYP21A2, CYP11B1, CYP17A1, HSD17B3, HSD3B2, ARMC5, and STAR using target capture-based deep sequencing; and Sanger sequencing was conducted for the family members to detect the potential mutations. The following results were obtained. In family 1, molecular genetics sequencing revealed a compound heterozygous mutation (c.293-13C>G/c.518T>A, p.I173N) in CYP12A2 in the patient and his brother. In family 2, all three female patients with adrenal myelolipomas were found to have a compound heterozygous mutation (c.1118A>T, p.H373L/c.1459_1467del9, p.D487_F489del) in CYP17A1. To avoid giant CAH-associated adrenal myelolipomas in adults, it is important to identify CAH early so that appropriate treatment can be initiated to interrupt the chronic adrenal hyperstimulation resulting from increased ACTH. Genetic testing and counseling could be useful in CAH.
Search for other papers by Yiqiang Huang in
Google Scholar
PubMed
Search for other papers by Lin-ang Wang in
Google Scholar
PubMed
Search for other papers by Qiubo Xie in
Google Scholar
PubMed
Search for other papers by Jian Pang in
Google Scholar
PubMed
Search for other papers by Luofu Wang in
Google Scholar
PubMed
Search for other papers by Yuting Yi in
Google Scholar
PubMed
Search for other papers by Jun Zhang in
Google Scholar
PubMed
Search for other papers by Yao Zhang in
Google Scholar
PubMed
Search for other papers by Rongrong Chen in
Google Scholar
PubMed
Search for other papers by Weihua Lan in
Google Scholar
PubMed
Search for other papers by Dianzheng Zhang in
Google Scholar
PubMed
Search for other papers by Jun Jiang in
Google Scholar
PubMed
Pheochromocytoma and paragangliomas (PCC/PGL) are neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and sympathetic/parasympathetic ganglia, respectively. Of clinical relevance regarding diagnosis is the highly variable presentation of symptoms in PCC/PGL patients. To date, the clear-cut correlations between the genotypes and phenotypes of PCC/PGL have not been entirely established. In this study, we reviewed the medical records of PCC/PGL patients with pertinent clinical, laboratory and genetic information. Next-generation sequencing (NGS) performed on patient samples revealed specific germline mutations in the SDHB (succinate dehydrogenase complex iron-sulfur subunit B) and SDHD (succinate dehydrogenase complex subunit D) genes and these mutations were validated by Sanger sequencing. Of the 119 patients, two were identified with SDHB mutation and one with SDHD mutation. Immunohistochemical (IHC) staining was used to analyze the expression of these mutated genes. The germline mutations identified in the SDH genes were c343C>T and c.541-542A>G in the SDHB gene and c.334-337delACTG in the SDHD gene. IHC staining of tumors from the c.343C>T and c.541-2A>G carriers showed positive expression of SDHB. Tumors from the c.334-337delACTG carrier showed no expression of SDHD and a weak diffused staining pattern for SDHB. We strongly recommend genetic testing for suspected PCC/PGL patients with a positive family history, early onset of age, erratic hypertension, recurrence or multiple tumor sites and loss of SDHB and/or SDHD expression. Tailored personal management should be conducted once a patient is confirmed as an SDHB and/or SDHD mutation carrier or diagnosed with PCC/PGL.
Search for other papers by Qiuli Liu in
Google Scholar
PubMed
Search for other papers by Gang Yuan in
Google Scholar
PubMed
Search for other papers by Dali Tong in
Google Scholar
PubMed
Search for other papers by Gaolei Liu in
Google Scholar
PubMed
Search for other papers by Yuting Yi in
Google Scholar
PubMed
Search for other papers by Jun Zhang in
Google Scholar
PubMed
Search for other papers by Yao Zhang in
Google Scholar
PubMed
Search for other papers by Lin-ang Wang in
Google Scholar
PubMed
Search for other papers by Luofu Wang in
Google Scholar
PubMed
Search for other papers by Dianzheng Zhang in
Google Scholar
PubMed
Search for other papers by Rongrong Chen in
Google Scholar
PubMed
Search for other papers by Yanfang Guan in
Google Scholar
PubMed
Search for other papers by Xin Yi in
Google Scholar
PubMed
Search for other papers by Weihua Lan in
Google Scholar
PubMed
Search for other papers by Jun Jiang in
Google Scholar
PubMed
Context
Von Hippel–Lindau (VHL) disease manifests as a variety of benign and malignant neoplasms. Previous studies of VHL disease have documented several genotype–phenotype correlations; however, many such correlations are still unknown. Increased identification of new mutations and patients with previously described mutations will allow us to better understand how VHL mutations influence disease phenotypes.
Patients and design
A total of 45 individuals from five unrelated families were evaluated, of which 21 patients were either diagnosed with VHL disease or showed strong evidence related to this disease. We compared the patients’ gene sequencing results with their medical records including CT or MRI scans, eye examinations and laboratory/pathological examinations. Patients were also interviewed to obtain information regarding their family history.
Results
We identified four missense mutations: c.239G>T (p.Ser80Ile), linked with VHL Type 2B, was associated with renal cell carcinoma, pheochromocytoma and hemangioma in the cerebellum; c.232A>T (p.Asn78Tyr) manifested as RCC alone and likely caused VHL Type 1; c.500G>A (p.Arg167Gln) mutation was more likely to cause VHL Type 2 than Type 1 as it preferentially induced Pheo and HB in the retina, cerebellum and spinal cord; c.293A>G (p.Try98Cys) was associated with Pheo and thus likely induced VHL Type 2.
Conclusions
Characterizing VHL disease genotype–phenotype correlations can enhance the ability to predict the risk of individual patients developing different VHL-related phenotypes. Ultimately, such insight will improve the diagnostics, surveillance and treatment of VHL patients.
Precis
Four missense mutations in VHL have been identified in 21 individuals when five unrelated Chinese families with VHL disease were analyzed; VHL mutations are highly associated with unique disease phenotypes.
